Cargando…
The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy
PURPOSE: Constructed from a theoretical framework, the coordinated undermining of survival paths in glioblastoma (GBM) is a combination of nine drugs approved for non-oncological indications (CUSP9; aprepitant, auranofin, captopril, celecoxib, disulfiram, itraconazole, minocycline, quetiapine, and s...
Autores principales: | Skaga, Erlend, Skaga, Ida Ø., Grieg, Zanina, Sandberg, Cecilie J., Langmoen, Iver A., Vik-Mo, Einar O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527541/ https://www.ncbi.nlm.nih.gov/pubmed/31028540 http://dx.doi.org/10.1007/s00432-019-02920-4 |
Ejemplares similares
-
Phenotypic and Expressional Heterogeneity in the Invasive Glioma Cells()()
por: Fayzullin, Artem, et al.
Publicado: (2018) -
Functional temozolomide sensitivity testing of patient-specific glioblastoma stem cell cultures is predictive of clinical outcome
por: Skaga, Erlend, et al.
Publicado: (2022) -
TBIO-18. ESTABLISHING A PIPELINE FOR INDIVIDUALIZED TREATMENT OPTIONS FOR PEDIATRIC BRAIN CANCER
por: Djirackor, Luna, et al.
Publicado: (2020) -
Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment
por: Skaga, Erlend, et al.
Publicado: (2019) -
Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?
por: Skaga, Erlend, et al.
Publicado: (2021)